240
Participants
Start Date
July 1, 2024
Primary Completion Date
October 31, 2027
Study Completion Date
February 29, 2028
ANV600
ANV600 administered by intravenous (IV) infusion
ANV600 + pembrolizumab (KEYTRUDA®)
ANV600 administered by intravenous (IV) infusion pembrolizumab (KEYTRUDA®) administered by intravenous (IV) infusion
RECRUITING
Fox Chase Cancer Center, Philadelphia
RECRUITING
Karmanos Cancer Institute, Detroit
RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
Cliniques Universitaires Saint-Luc, Brussels
RECRUITING
Institut Bergonie, Bordeaux
RECRUITING
CEPCM - AP-HM Hopital de la Timone, Marseille
RECRUITING
Oncopole Claudius Regaud, Toulouse, Toulouse
RECRUITING
Institut Gustave Roussy, Villejuif
RECRUITING
Charite Universitaetsmedizin Berlin, Berlin
RECRUITING
Krankenhaus Nordwest - Institut für Klinisch-Onkologische Forschung (IKF), Frankfurt
RECRUITING
Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz, Mainz
RECRUITING
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL), Amsterdam
RECRUITING
Vall d'Hebron Institute of Oncology (VHIO), Barcelona
RECRUITING
START Madrid CIOCC, Madrid
RECRUITING
Clinica Universidad de Navarra - Pamplona, Pamplona
RECRUITING
INCLIVA Foundation, Valencia
RECRUITING
Ente Ospedaliero Cantonale - Istituto Oncologico della Svizzera Italiana, Bellinzona
RECRUITING
Cantonal Hospital St Gallen, Sankt Gallen
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Anaveon AG
INDUSTRY